4sCAR-DLL3 CAR-T therapy / SZGIMI - LARVOL DELTA

DLL3 CAR-T Therapy Targeting Brain Tumors (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Sep 2029 ➔ Dec 2028 | Initiation date: Sep 2025 ➔ Jun 2027 | Trial primary completion date: Dec 2028 ➔ May 2028

Trial completion date • Trial initiation date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • DLL3

DLL3 CAR-T Therapy Targeting Brain Tumors (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute

New P1/2 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • DLL3